Health X Q1 FY27: Rapid growth, improving gross margin, and an investment-led playbook

Health X Platform Limited reported a sharp jump in scale in Q1 FY27, with revenue from operations at INR 440.3 crore, up 58.1% year-on-year and 16.4% quarter-on-quarter. Gross profit rose to INR 34.2 crore, with gross margin at 7.8%. EBITDA remained negative at INR minus 14.9 crore, but the loss narrowed sequentially from the prior quarter. Profit after tax stood at INR 2.0 crore.

Management described the quarter as the strongest in the company’s history and emphasized that the building blocks put in place over the previous year across Retailer Shakti, SastaSundar, fulfilment infrastructure, technology and the JITO private label are now translating into stronger revenue momentum. The company’s model is positioned as an integrated system where procurement, fulfilment and technology are common, while customer acquisition differs by channel.

Retailer Shakti continues to be the core growth engine. In Q1 FY27, Retailer Shakti generated INR 361.9 crore of revenue, while SastaSundar contributed INR 48.1 crore and diagnostics remained small at INR 0.7 crore. Financial services revenue, which management clarified as treasury income, was INR 49.0 crore for the quarter, taking total revenue to INR 459.7 crore.

Platforms and order economics

A recurring theme in the management commentary was that growth quality is being supported by order mix and repeat usage. For Retailer Shakti, management highlighted that 69.4% of business came from orders above INR 2,500 and 42.4% from orders above INR 5,000, based on the disclosed Jan to March 2026 data. On the consumer side, SastaSundar reported 69.2% of orders above INR 1,000, while also serving smaller baskets to drive frequency.

The investor presentation also positioned the company as capable of servicing Tier 1 through rural markets. For the Jan to March 2026 quarter, the company disclosed that 77.8% of SastaSundar sales and 67% of Retailer Shakti sales came from Tier 2 and Tier 3 markets, supporting the claim that the model is not dependent on metros.

Margin trajectory and the role of JITO

Gross margin remains the key financial variable to watch. In the investor deck, the company presented an expansion in gross margin to 7.9% in the June 2026 quarter compared with 7.5% in March 2026 and 6.6% in June 2025, excluding financial services revenue. On the call, management discussed an eventual consolidated gross margin potential of around 12% over time, while indicating an 8% plus gross margin expectation for the year.

JITO, the company’s private-label initiative for generic medicines, is positioned as a margin opportunity and an affordability lever. The company disclosed that JITO products can be priced up to 60% lower than leading branded alternatives and presented quality assurance claims including WHO-GMP manufacturing and NABL-accredited lab testing support. Management disclosed early traction, with JITO sales increasing from INR 25 lakh in Q4 FY26 to INR 79 lakh in Q1 FY27, though it remains a small base.

Investment phase, technology focus, and fulfilment expansion

Despite growth, the company is still in an investment phase. EBITDA remained negative in Q1 FY27 and management explicitly stated that SastaSundar is not expected to be EBITDA positive for the next two to three years, as it continues to invest in brand, technology and expansion. Management characterized almost all revenue as contribution margin positive, but near-term operating losses reflect upfront capability building.

Technology is a central part of the strategy. The investor deck outlined AI integration across counselling, consultation validation, smart health records and backend automation. On the call, management said it is working to launch an AI-monitored Retail Air product for retailers in the current quarter. In response to questions on operating burn, management provided a broad split, indicating around 25% to 30% of the burn is marketing and advertising and around 40% to 45% is technology-related cost.

Operational scale is being supported by fulfilment capacity expansion. The deck highlighted existing warehouse capacity of 221,300 sq ft across West Bengal, Noida and Guwahati, with additional planned capacity of 505,000 sq ft including new fulfilment centers in Lucknow, Udaipur and Patha. Management stated that existing infrastructure, along with side extensions, can support scale up to roughly INR 2,500 to 3,000 crore of revenue without major constraints.

Takeaways

Health X’s Q1 FY27 numbers show a clear return to strong growth, with improving gross profit and narrowing EBITDA losses. Retailer Shakti remains the primary driver, while SastaSundar is being rebuilt with a franchise-led Healthbuddy model and technology investments. The gross margin trajectory, execution on fulfilment expansion, and the pace of JITO scaling are likely to be the most important operating indicators. At the same time, the company’s profitability remains influenced by other income, and segment-level profitability disclosure is still limited due to integrated cost structures.

The quarter reflects strong momentum, but the investment cycle is still underway. Investors will likely track whether operating leverage continues to improve as the company scales into new geographies and adds private label mix.